Compare · NVO vs TVRD
NVO vs TVRD
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tvardi Therapeutics Inc. (TVRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TVRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 6320.9x TVRD ($29.1M).
- Over the past year, NVO is down 34.2% and TVRD is down 85.4% - NVO leads by 51.1 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for TVRD).
- NVO has more recent analyst coverage (25 ratings vs 11 for TVRD).
- Company
- Novo Nordisk A/S
- Tvardi Therapeutics Inc.
- Price
- $41.18+6.93%
- $3.11+5.42%
- Market cap
- $183.82B
- $29.1M
- 1M return
- +13.32%
- -5.76%
- 1Y return
- -34.24%
- -85.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest TVRD
- SEC Form DEFA14A filed by Tvardi Therapeutics Inc.
- SEC Form DEF 14A filed by Tvardi Therapeutics Inc.
- Tvardi Therapeutics downgraded by Barclays with a new price target
- SEC Form S-8 filed by Tvardi Therapeutics Inc.
- SEC Form POS EX filed by Tvardi Therapeutics Inc.
- SEC Form 424B3 filed by Tvardi Therapeutics Inc.
- SEC Form 10-K filed by Tvardi Therapeutics Inc.
- Tvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
- SEC Form 424B3 filed by Tvardi Therapeutics Inc.